Trial · NCT03172624
Adverse events114
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 114
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 2 | 32 | |
| other | Alanine aminotransferase increased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 0 | 32 | |
| other | Anemia | Blood and lymphatic system disorders | R/M Adenoid Cystic Carcinoma (ACC) | 4 | 32 | |
| other | Anemia | Blood and lymphatic system disorders | R/M SGC of Any Histology, Except ACC (Non ACC) | 1 | 32 | |
| other | Aspartate aminotransferase increased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 4 | 32 | |
| other | Aspartate aminotransferase increased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 2 | 32 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | R/M Adenoid Cystic Carcinoma (ACC) | 0 | 32 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | R/M SGC of Any Histology, Except ACC (Non ACC) | 4 | 32 | |
| other | Hyponatremia | Metabolism and nutrition disorders | R/M Adenoid Cystic Carcinoma (ACC) | 4 | 32 | |
| other | Hyponatremia | Metabolism and nutrition disorders | R/M SGC of Any Histology, Except ACC (Non ACC) | 5 | 32 | |
| other | Hypophosphatemia | Metabolism and nutrition disorders | R/M Adenoid Cystic Carcinoma (ACC) | 2 | 32 | |
| other | Hypophosphatemia | Metabolism and nutrition disorders | R/M SGC of Any Histology, Except ACC (Non ACC) | 2 | 32 | |
| other | Lymphocyte count decreased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 11 | 32 | |
| other | Lymphocyte count decreased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 14 | 32 | |
| other | Neutrophil count decreased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 2 | 32 | |
| other | Neutrophil count decreased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 3 | 32 | |
| other | White blood cell decreased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 1 | 32 | |
| other | White blood cell decreased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 3 | 32 | |
| serious | Alanine aminotransferase increased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 1 | 32 | |
| serious | Alanine aminotransferase increased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 0 | 32 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03172624/events